Recent Finacing
Recent Raise
Eccogene is a Shanghai clinical-stage biopharmaceutical developing therapies for metabolic and immune diseases, including ECC5004 (small-molecule GLP‑1 agonist), ECC4703 (THRβ agonist), and ECC0509 (SSAO/VAP‑1 inhibitor in Phase I).
